SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCLN
  • CUSIP: 80862K10
  • Web:
  • Market Cap: $481.11 million
  • Outstanding Shares: 51,732,000
Average Prices:
  • 50 Day Moving Avg: $9.68
  • 200 Day Moving Avg: $9.96
  • 52 Week Range: $8.55 - $15.02
  • Trailing P/E Ratio: 13.22
  • Foreward P/E Ratio: 8.53
  • P/E Growth: 0.75
Sales & Book Value:
  • Annual Revenue: $166.49 million
  • Price / Sales: 2.89
  • Book Value: $4.52 per share
  • Price / Book: 2.06
  • EBIDTA: $39.03 million
  • Net Margins: 23.20%
  • Return on Equity: 22.10%
  • Return on Assets: 19.47%
  • Current Ratio: 7.49%
  • Quick Ratio: 6.93%
  • Average Volume: 238,131 shs.
  • Beta: 1.66
  • Short Ratio: 6.82

Frequently Asked Questions for SciClone Pharmaceuticals (NASDAQ:SCLN)

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

How were SciClone Pharmaceuticals' earnings last quarter?

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) released its quarterly earnings data on Monday, March, 6th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by $0.03. The firm earned $44.06 million during the quarter. SciClone Pharmaceuticals had a net margin of 23.20% and a return on equity of 22.10%. View SciClone Pharmaceuticals' Earnings History.

Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued 12-month price targets for SciClone Pharmaceuticals' shares. Their forecasts range from $14.00 to $14.00. On average, they anticipate SciClone Pharmaceuticals' share price to reach $14.00 in the next year. View Analyst Ratings for SciClone Pharmaceuticals.

Who are some of SciClone Pharmaceuticals' key competitors?

Who owns SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.73%), Dimensional Fund Advisors LP (5.61%), Renaissance Technologies LLC (4.05%), Acadian Asset Management LLC (3.46%), Stonepine Capital Management LLC (3.23%) and State Street Corp (3.04%). Company insiders that own SciClone Pharmaceuticals stock include Chuncai Meng, Friedhelm Blobel, Hong Zhao, Lan Xie, Nancy T Chang, Richard J Hawkins and Wilson Wai-Shun Cheung. View Institutional Ownership Trends for SciClone Pharmaceuticals.

Who sold SciClone Pharmaceuticals stock? Who is selling SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sensato Investors LLC, LSV Asset Management, ClariVest Asset Management LLC, Acadian Asset Management LLC, Alliancebernstein L.P., Goldman Sachs Group Inc., Cornerstone Capital Management Holdings LLC. and TFS Capital LLC. Company insiders that have sold SciClone Pharmaceuticals stock in the last year include Friedhelm Blobel, Lan Xie, Nancy T Chang and Wilson Wai-Shun Cheung. View Insider Buying and Selling for SciClone Pharmaceuticals.

Who bought SciClone Pharmaceuticals stock? Who is buying SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., JPMorgan Chase & Co., Menta Capital LLC, State Street Corp, Nine Chapters Capital Management LLC and Bank of America Corp DE. View Insider Buying and Selling for SciClone Pharmaceuticals.

How do I buy SciClone Pharmaceuticals stock?

Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of SciClone Pharmaceuticals stock cost?

One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $9.30.

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (50.54% upside)

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Maxim GroupSet Price TargetBuy$17.00 -> $14.00HighView Rating Details
7/9/2015BWS FinancialDowngradeHold -> SellN/AView Rating Details
6/29/2015MLV & Co.Initiated CoverageBuyN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings History by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017Q4 2016$0.15$0.12$44.06 millionViewListenView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)
Current Year EPS Consensus Estimate: $0.92 EPS
Next Year EPS Consensus Estimate: $1.09 EPS


Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 76.93%
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/24/2017Friedhelm BlobelCEOSell21,464$9.32$200,044.48View SEC Filing  
5/22/2017Friedhelm BlobelCEOSell18,536$9.44$174,979.84View SEC Filing  
5/11/2017Friedhelm BlobelCEOSell18,226$10.00$182,260.00View SEC Filing  
4/28/2017Friedhelm BlobelCEOSell4,400$10.01$44,044.00View SEC Filing  
4/24/2017Friedhelm BlobelCEOSell40,000$9.56$382,400.00View SEC Filing  
3/22/2017Friedhelm BlobelCEOSell40,000$9.47$378,800.00View SEC Filing  
3/16/2017Lan XieVPSell1,000$9.60$9,600.00View SEC Filing  
3/6/2017Friedhelm BlobelCEOSell3,087$10.30$31,796.10View SEC Filing  
3/3/2017Friedhelm BlobelCEOSell26,913$10.01$269,399.13View SEC Filing  
2/24/2017Friedhelm BlobelCEOSell823$9.71$7,991.33View SEC Filing  
2/23/2017Friedhelm BlobelCEOSell39,177$9.83$385,109.91View SEC Filing  
1/25/2017Friedhelm BlobelCEOSell8,868$10.54$93,468.72View SEC Filing  
1/24/2017Friedhelm BlobelCEOSell61,132$10.44$638,218.08View SEC Filing  
1/5/2017Friedhelm BlobelCEOSell9,600$11.02$105,792.00View SEC Filing  
12/22/2016Friedhelm BlobelCEOSell70,000$10.55$738,500.00View SEC Filing  
11/22/2016Friedhelm BlobelCEOSell70,000$10.22$715,400.00View SEC Filing  
11/14/2016Friedhelm BlobelCEOSell30,000$10.27$308,100.00View SEC Filing  
10/27/2016Friedhelm BlobelCEOSell40,000$9.30$372,000.00View SEC Filing  
10/26/2016Wilson Wai-Shun CheungCFOSell149,962$10.00$1,499,620.00View SEC Filing  
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.00View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.00View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.20View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for SciClone Pharmaceuticals (NASDAQ:SCLN)
Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
DateHeadline logoFriedhelm Blobel Sells 21,464 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock - May 25 at 8:05 PM logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Friedhelm Blobel Sells 18,536 Shares - May 23 at 10:37 PM logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $182,260.00 in Stock - May 15 at 7:50 PM logoSciClone Pharmaceuticals, Inc. (SCLN) Given a $14.00 Price Target by Maxim Group Analysts - May 13 at 11:56 PM logoEdited Transcript of SCLN earnings conference call or presentation 10-May-17 8:30pm GMT - May 11 at 8:02 AM logoSciClone Reports First Quarter 2017 Financial Results - May 10 at 7:57 PM logoSciClone posts 1Q profit - May 10 at 7:57 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : May 10, 2017 - May 10 at 11:01 AM logoSciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017 - May 4 at 9:19 AM logoSciClone Pharmaceuticals (SCLN) Receiving Somewhat Favorable News Coverage, Report Shows - May 3 at 2:14 PM logoSomewhat Positive News Coverage Very Likely to Impact SciClone Pharmaceuticals (SCLN) Share Price - April 30 at 5:44 PM logoInsider Selling: SciClone Pharmaceuticals, Inc. (SCLN) CEO Sells 4,400 Shares of Stock - April 29 at 1:30 AM logoSciClone Pharmaceuticals (SCLN) Given Daily News Impact Score of 0.32 - April 28 at 12:40 AM logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : April 26, 2017 - April 26 at 9:01 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : April 25, 2017 - April 25 at 9:59 AM logoFriedhelm Blobel Sells 40,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock - April 24 at 11:06 PM logoSciClone Pharmaceuticals (SCLN) Getting Somewhat Negative Press Coverage, Report Finds - April 23 at 4:47 PM logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : April 11, 2017 - April 11 at 9:49 AM logoSciClone To Present At Needham Healthcare... - March 27 at 9:17 AM logoSciClone To Present At Needham Healthcare Conference On April 4, 2017 - March 27 at 9:17 AM logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $378,800.00 in Stock - March 23 at 7:34 PM logoSCICLONE PHARMACEUTICALS INC Financials - March 15 at 7:58 PM logoInsider Selling: SciClone Pharmaceuticals, Inc. (SCLN) CEO Sells 3,087 Shares of Stock - March 8 at 11:54 PM logoSciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha - March 7 at 7:35 PM logoEdited Transcript of SCLN earnings conference call or presentation 6-Mar-17 1:30pm GMT - March 7 at 9:18 AM logoSciClone Reports 2016 Financial Results And 2017 Outlook - March 6 at 11:38 AM logoQ4 2016 SciClone Pharmaceuticals Inc Earnings Release - Before Market Open - March 6 at 11:38 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - March 6 at 11:38 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Fin - February 28 at 7:21 PM logoSciClone Pharmaceuticals To Report Fourth Quarter And Full Year 2016 Financial Results On March 6, 2017 - February 21 at 5:09 PM logoSciClone To Present At BIO CEO & Investor Conference On February 13, 2017 - February 2 at 12:38 AM logoSCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - January 6 at 9:50 PM



SciClone Pharmaceuticals (SCLN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff